Andersen MH - Search Results

1

Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.

Sørensen RB, Køllgaard T, Andersen RS, van den Berg JH, Svane IM, Straten Pt, Andersen MH. Sørensen RB, et al. Among authors: andersen rs, andersen mh. Cancer Res. 2011 Mar 15;71(6):2038-44. doi: 10.1158/0008-5472.CAN-10-3403. Cancer Res. 2011. PMID: 21406395

2

Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.

Andersen MH, Pedersen LO, Becker JC, Straten PT. Andersen MH, et al. Cancer Res. 2001 Feb 1;61(3):869-72. Cancer Res. 2001. PMID: 11221872

3

Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. Andersen MH, et al. Cancer Res. 2001 Aug 15;61(16):5964-8. Cancer Res. 2001. PMID: 11507035

4

Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression.

Andersen MH, Keikavoussi P, Bröcker EB, Schuler-Thurner B, Jonassen M, Søndergaard I, Straten PT, Becker JC, Kämpgen E. Andersen MH, et al. Int J Cancer. 2001 Dec 15;94(6):820-4. doi: 10.1002/ijc.1536. Int J Cancer. 2001. PMID: 11745484 Free article.

5

HLA-B35-restricted immune responses against survivin in cancer patients.

Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. Reker S, et al. Among authors: andersen mh. Int J Cancer. 2004 Mar 1;108(6):937-41. doi: 10.1002/ijc.11634. Int J Cancer. 2004. PMID: 14712500 Free article.

6

Identification of novel survivin-derived CTL epitopes.

Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. Reker S, et al. Among authors: andersen mh. Cancer Biol Ther. 2004 Feb;3(2):173-9. doi: 10.4161/cbt.3.2.611. Epub 2004 Feb 1. Cancer Biol Ther. 2004. PMID: 14726703

7

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.

Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, thor Straten P. Andersen MH, et al. Semin Cancer Biol. 2003 Dec;13(6):449-59. doi: 10.1016/j.semcancer.2003.09.009. Semin Cancer Biol. 2003. PMID: 15001164 Review.

8

The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses.

Andersen MH, Reker S, Becker JC, thor Straten P. Andersen MH, et al. J Invest Dermatol. 2004 Feb;122(2):392-9. doi: 10.1046/j.0022-202X.2004.22242.x. J Invest Dermatol. 2004. PMID: 15009721 Free article.

9

Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP.

Andersen MH, Becker JC, Straten Pt. Andersen MH, et al. J Invest Dermatol. 2004 May;122(5):1336-7. doi: 10.1111/j.0022-202X.2004.22508.x. J Invest Dermatol. 2004. PMID: 15140242 Free article. No abstract available.

10

Immunogenicity of constitutively active V599EBRaf.

Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Bröcker EB, Straten Pt, Rapp UR, Becker JC. Andersen MH, et al. Cancer Res. 2004 Aug 1;64(15):5456-60. doi: 10.1158/0008-5472.CAN-04-0937. Cancer Res. 2004. PMID: 15289355

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

378 results

Search Page